Asahi Kasei Therapeutics
secondary
spacer
Corporate Profile##outline
In Japan and other major markets in Asia, Asahi Kasei Therapeutics develops and provides novel therapies centered on the field of orthopedics, as well as critical/intensive care, immunology, urology, and the central nervous system. In September 2026, the main pharmaceutical operations in the U.S. and Europe adopted the unified brand of Asahi Kasei Therapeutics. We are growing as a global specialty pharma company that addresses unmet medical needs and drives the growth of the Asahi Kasei Group.
spacer
column-header
Trade name
Asahi Kasei Therapeutics Corp.
https://www.asahikasei-pharma.co.jp/en/
Global website https://www.aktx.com/
Main businesses
Pharmaceuticals
Home office
Hibiya Mitsui Tower, 1-1-2 Yurakucho, Chiyoda-ku, Tokyo 100-0006 Japan
President
Daisuke Okajima
Paid-in capital
¥3,000 million
Shareholder
Asahi Kasei Corp.
Phone
+81-(0)3-6699-3600
(as of September 30, 2026)
Officers##officer
column-header
Yoshikazu Aoki
Chairman & Representative Director
Daisuke Okajima
President & Representative Director,
Presidential Executive Officer
Presidential Executive Officer
Yasuo Nakamura
Director, Senior Executive Officer
Yutaka Osawa
Executive Officer
Kazunobu Konishi
Executive Officer
Hiroaki Hayashi
Executive Officer
Katsunori Oono
Corporate Auditor
(as of June 23, 2026)
column-header